Cellenkos Receives FDA Fast Track Designation for CK0803 in Amyotrophic Lateral Sclerosis (ALS)
The FDA has granted Fast Track designation to CK0803 for ALS, an investigational therapy that showed an approximately 60% decrease in neurofilament light chain and a 200% increase in plasma IL-10 levels during initial clinical evaluations. Cord blood-derived, CNS-homing T-regulatory cell...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.